Personalized mRNA Cancer Vaccine Enters Phase III: 72% Response Rate in Advanced Melanoma

Personalized mRNA Cancer Vaccine Enters Phase III

On February 14, 2028, BioNTech and Roche's Genentech published Phase III clinical trial results in the New England Journal of Medicine: personalized mRNA cancer vaccine BNT122 (codename Autogene Cevumeran) combined with PD-1 inhibitor pembrolizumab achieved a 72% objective response rate (ORR) and 33% complete response rate (CR) in advanced melanoma.

"BNT122 isn't a universal vaccine — it's custom-made for each patient," said BioNTech CEO Ugur Sahin. "We extract mutation information from the patient's tumor and design mRNA sequences that target only that patient's cancer cells."

How It Works

BNT122's treatment process has three steps: First, tumor biopsy tissue undergoes whole-exome and RNA sequencing to identify up to 20 neoantigens. Then, BioNTech's AI platform BioNTwin designs mRNA sequences encoding these neoantigens within 48 hours. Finally, the mRNA is encapsulated in lipid nanoparticles and delivered via IV injection.

Once in the body, the mRNA is taken up by antigen-presenting cells and translated into neoantigen proteins, activating the patient's own T cells to mount a tumor-specific immune attack.

Clinical Data

The Phase III trial enrolled 687 Stage III-IV melanoma patients across 47 global sites. At 18-month median follow-up:

• BNT122 + pembrolizumab: ORR 72%, CR 33%, median PFS 16.8 months
• Pembrolizumab alone: ORR 45%, CR 16%, median PFS 10.2 months

The difference was statistically significant (P<0.001). Grade 3+ adverse events occurred in 28% of the BNT122 group versus 24% in the control group, with no new safety signals.

Manufacturing Challenges

Each patient's vaccine is unique, precluding mass production. BioNTech disclosed that the full process from biopsy to vaccine delivery takes approximately 6 weeks. Production capacity is roughly 15,000 doses per year across facilities in Marburg, Germany and Boston — enough for approximately 1,875 patients.

Pricing and Access

Analysts estimate treatment costs will range from $100,000 to $150,000 per patient. WHO cancer program lead Andre Ilbawi said: "The clinical results are remarkable, but if only wealthy patients can afford them, we face a new health inequality."

BioNTech has committed to exploring access programs for low- and middle-income countries through GAVI partnership.

Expansion

BioNTech has initiated Phase II trials in non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Preliminary colorectal cancer data shows approximately 58% ORR with chemotherapy combination.